InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI’s AI platform...